Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance

Soligenix Inc. (NASDAQ: SNGX) is pioneering the development of SGX943, a therapy based on dusquetide, an Innate Defense Regulator (IDR) that modulates the body's immune response to fight bacterial infections without directly targeting the bacteria. This innovative approach not only promotes the clearance of infections but also reduces inflammation, offering a broad-spectrum solution to the growing problem of antibiotic resistance. The company's focus on areas with significant unmet medical needs highlights the potential impact of SGX943 in transforming treatment paradigms for bacterial infections.

The development of SGX943 is part of Soligenix's broader portfolio, which includes specialized biotherapeutics and public health solutions aimed at addressing rare diseases and critical health challenges. With antibiotic resistance posing a significant threat to global health, the advancement of alternative treatments like SGX943 represents a crucial step forward in medical science. For more information on Soligenix's efforts to combat antibiotic resistance, visit https://ibn.fm/PZfm9.